Biodexa Registers 220M Shares Underlying New Series P Warrants for Armistice Resale
BDRX is trading near its 52-week low of $0.61 (6.7% above the low) on light trading volume (0.1× avg).
Summary
Biodexa registers 220.4M ordinary shares underlying new Series P Warrants for resale by Armistice Capital, following a September warrant inducement that raised ~$2.3M at a reduced $1.05 exercise price.
Key Events · Financing and Capital Events · BDRX
-
220.4M Shares Registered for Armistice Resale
F-1 registers 220,421,800 ordinary shares (4,408,436 ADSs) underlying Series P Warrants issued to Armistice Capital in the September 15, 2026 warrant inducement.
-
September Warrant Inducement Terms
2,204,218 existing Series M/N/O warrants were exercised at a reduced $1.05 per ADS, generating ~$2.3M gross proceeds; 4,408,436 new Series P Warrants were issued at $1.05 exercise price, exercisable for five years.
-
Potential Dilution from Full Exercise
If all Series P Warrants are exercised, total ordinary shares outstanding would rise from 209,695,831 to 430,117,631 — an increase of 220,421,800 shares, or roughly 105% of the current share count.
-
No Proceeds to Company from Resales
Biodexa receives no proceeds from Armistice's resale of the shares; the company only receives cash if Armistice exercises the Series P Warrants for cash at $1.05 per ADS.
Analysis · BDRX · Life Sciences
This F-1 registers 220,421,800 ordinary shares (4,408,436 ADSs) underlying Series P Warrants issued to Armistice Capital in the September 15 warrant inducement. The inducement raised ~$2.3M by exercising 2,204,218 existing warrants at a reduced $1.05 per ADS, and issued 4,408,436 new Series P Warrants at the same $1.05 exercise price. If all Series P Warrants are exercised, total ordinary shares outstanding would rise from 209,695,831 to 430,117,631 — an increase of 220,421,800 shares, or roughly 105% of the current share count. The company receives no proceeds from resales by Armistice, only from any cash exercise of the warrants. This is a continuation of Biodexa's aggressive warrant-inducement financing pattern, with Armistice as the sole selling shareholder holding a 9.99% beneficial ownership blocker.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.6% of the 919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $709.4K. The 52-week trading range was $0.61 to $59.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.